Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

2.76
+0.14005.34%
Post-market: 2.780.0192+0.70%19:39 EDT
Volume:4.59M
Turnover:12.79M
Market Cap:708.80M
PE:-25.29
High:2.86
Open:2.67
Low:2.66
Close:2.62
52wk High:4.18
52wk Low:0.6925
Shares:256.81M
Float Shares:237.00M
Volume Ratio:1.01
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1091
EPS(LYR):-0.1091
ROE:97.76%
ROA:9.30%
PB:-2.35
PE(LYR):-25.29

Loading ...

Esperion Therapeutics Q4 Basic EPS USD 0.26

THOMSON REUTERS
·
Mar 10

Esperion Therapeutics Q4 Net Income USD 61.831 Million VS. Ibes Estimate USD 70 Million

THOMSON REUTERS
·
Mar 10

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Mar 10

U.S. Earnings Preview: Before Market Open March 10

Dow Jones
·
Mar 10

HLS Therapeutics Announces Nilemdotm (Bempedoic Acid) Is NOW Available in Canada for the Reduction of Ldl-Cholesterol in Patients at Risk of Cardiovascular Disease

THOMSON REUTERS
·
Mar 05

Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)

TIPRANKS
·
Mar 04

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires Live
·
Mar 04

Esperion Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Mar 04

Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Esperion (ESPR)

TIPRANKS
·
Mar 03

Esperion Therapeutics to acquire Corstasis Therapeutics for $75 million upfront

Reuters
·
Mar 03

Esperion Therapeutics Inc - to Finance Acquisition Through Credit Facilities

THOMSON REUTERS
·
Mar 03

Esperion Therapeutics Inc - Deal Includes $75 Mln Cash Payment and $180 Mln Milestone Payments

THOMSON REUTERS
·
Mar 03

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)

THOMSON REUTERS
·
Mar 03

Esperion Therapeutics Inc - Corstasis Shareholders Eligible for up to $180 Mln in Milestones

THOMSON REUTERS
·
Mar 03

Esperion Therapeutics Inc. Schedules Quarterly and Full-Year Financial Results Webcast

Reuters
·
Feb 24

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 24

Esperion to Participate in 2026 Citizens Life Sciences Conference Webcast

Reuters
·
Feb 18

Esperion Therapeutics: Strengthened Bempedoic Acid Patent Protection and Growing Cardiovascular Franchise Support Buy Rating

TIPRANKS
·
Feb 18

Esperion reaches settlement agreement with Alkem

TIPRANKS
·
Feb 17

Esperion Faces Ongoing Patent Litigation Over NEXLETOL and NEXLIZET Generics

Reuters
·
Feb 17